Acrivon Therapeutics (ACRV) Change in Acquisitions & Divestments (2022 - 2026)

Acrivon Therapeutics (ACRV) has reported Change in Acquisitions & Divestments for 5 consecutive years, with $30.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 24.05% year-over-year to $30.0 million; the TTM figure through Mar 2026 stood at $140.0 million (down 11.63% YoY), while the FY2025 annual figure was $149.5 million, down 2.87% from the prior year.
• Change in Acquisitions & Divestments fell to $30.0 million in Q1 2026 per ACRV's latest filing, from $35.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $50.0 million in Q4 2024 and bottomed at $6.0 million in Q4 2022.
• Historically, Change in Acquisitions & Divestments has averaged $32.0 million across 5 years, with a median of $35.0 million in 2024.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments soared 538.33% — and 2025, when it slumped 30.0%.
• Acrivon Therapeutics' Change in Acquisitions & Divestments stood at $6.0 million in 2022, then jumped by 538.33% to $38.3 million in 2023, then surged by 30.66% to $50.0 million in 2024, then fell by 30.0% to $35.0 million in 2025, then decreased by 14.29% to $30.0 million in 2026.
• Business Quant data shows ACRV's Change in Acquisitions & Divestments at $30.0 million in Q1 2026, $35.0 million in Q4 2025, and $40.0 million in Q3 2025.